Lawrence T S, Davis M A
Department of Radiation Oncology, University of Michigan, Ann Arbor 48109.
Int J Radiat Oncol Biol Phys. 1989 May;16(5):1243-6. doi: 10.1016/0360-3016(89)90291-5.
The halogenated pyrimidines 5-chloro-2'-deoxycytidine (CldCyd) and 5-bromo-2'-deoxycytidine (BrdCyd) can act as radiosensitizers and cytotoxic agents. It was hypothesized that tumor cells and normal cells might use different metabolic pathways to incorporate these halogenated deoxycytidines into DNA. This difference could potentially be exploited to produce selective radiosensitization and cytotoxicity of human tumor cells compared to normal human fibroblasts. This hypothesis was tested using two human melanoma cell lines and two normal fibroblast cell lines. Either CldCyd or BrdCyd alone caused both cytotoxicity and radiosensitization of tumor and normal cells. The addition of the cytidine deaminase inhibitor tetrahydrouridine (H4U) significantly protected the normal cells but had relatively little effect on the tumor cells. These data indicate that it may be possible to exploit differences between the pyrimidine metabolism of normal cells and melanoma cells to improve the therapeutic index of halogenated pyrimidines both as radiosensitizers and as cytotoxic agents.
卤代嘧啶5-氯-2'-脱氧胞苷(CldCyd)和5-溴-2'-脱氧胞苷(BrdCyd)可作为放射增敏剂和细胞毒性剂。据推测,肿瘤细胞和正常细胞可能利用不同的代谢途径将这些卤代脱氧胞苷掺入DNA。与正常人类成纤维细胞相比,这种差异有可能被用于产生人类肿瘤细胞的选择性放射增敏和细胞毒性。使用两个人类黑色素瘤细胞系和两个正常成纤维细胞系对这一假设进行了测试。单独使用CldCyd或BrdCyd都会导致肿瘤细胞和正常细胞的细胞毒性和放射增敏。胞苷脱氨酶抑制剂四氢尿苷(H4U)的添加显著保护了正常细胞,但对肿瘤细胞的影响相对较小。这些数据表明,利用正常细胞和黑色素瘤细胞嘧啶代谢的差异来提高卤代嘧啶作为放射增敏剂和细胞毒性剂的治疗指数或许是可行的。